$PRME Cashflow Statement | Understand Stock

$PRME

$4.35 +$0.74 (20.5%) Close

$PRME Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Cash flows used in operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Non cash research and development expense for licenses
Non cash consideration received under related party collaboration arrangement
Non cash payment to Beam
Non cash lease expense
Depreciation expense
Change in fair value of short-term investment — related party
Loss on disposal of property and equipment
Amortization of premiums and discount on short-term investments
Deferred income taxes
Change in fair value of preferred stock tranche right liability
Change in fair value of anti-dilution obligation
Change in fair value of related party short-term investment
Non cash other income (expense)

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Accrued settlement payment — related party
Deferred revenue — related party
Lease liability
Net cash used in operating activities
Cash flows (used in) provided by investing activities:
Maturities of investments
Sales of investments — related party
Purchases of investments
Purchases of property and equipment
Payments of security deposits
Return (payment) of security deposit
Net cash (used in) provided by investing activities
Cash flows provided by financing activities:
Proceeds from the issuance of convertible preferred stock
Cash received in advance from issuance of convertible preferred stock series A
Proceeds from follow-on offering, net of issuance costs
Proceeds from research and development funding liability
Net proceeds from stock option exercises
Proceeds from initial public offering, net of underwrites discounts and commissions and deferred offering costs
Payments of deferred offering costs
Proceeds from ESPP offerings
Proceeds from issuance of common stock under the BMS Securities Purchase Agreement — related party
Proceeds from issuance of pre-funded warrants, net of issuance costs
Net cash provided by financing activities

Net change in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Less: restricted cash
Total cash, and cash equivalents
Supplemental cash flow information:
Right-of-use assets obtained in exchange for new operating lease liabilities
Decrease in right-of-use assets due to lease termination
Increase in right-of-use assets upon settlement with landlord
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses
Accretion of preferred stock to redemption value
Short-term investment in connection with related party collaboration arrangement
Unrealized loss on short-term investments
Conversion of convertible preferred stock to common stock upon closing of initial public offering
Settlement of Series A preferred stock tranche obligation
Issuance of Series A preferred stock at a price below fair value
Settlement of anti-dilution obligation
Settlement of related party forward contract
Cash taxes paid
Deferred offering costs included in accounts payable and accrued expenses at period end

Comments